The study, presented at Heart Failure 2022, investigated the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).
1. Study Background
3. Study Design, Eligibility Criteria & Outcome Measures
4. Key Findings
5. Take-Home Messages
6. Next Steps
Recorded at Heart Failure 2022, Madrid.
Videographers: Oliver Miles, Tom Green and Mike Knight
Interviewer: Mirjam Boros